Bladder cancer

UPDATED --- New hope for patients progressing after prior treatment for mUCa

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Образовательная цель: Identify appropriate treatment options for patients progressing after prior treatment for metastatic urothelial carcinoma (UCa).
Специальность: Medical oncology, urology, clinical oncology
Целевая аудитория : Specialists (CME: basic, intermediate), Residents (senior)
Самое последнее обновление : October 2024
Фон:

Regulatory approval status of drugs limited to the metastatic UCa setting (status 1 October 2024)

ChT: chemotherapy; CPS: combined positive score; PD-(L)1: programmed death-(ligand) 1

In all cases presented in this topic, it is assumed that the relevant antibodies/tests are used for PD-L1 and FGFR testing.

This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please refer to your local prescribing information.